Baxter begins Phase I cancer trial of anti-MIF antibody
The open label study will assess the safety, tolerability and optimal dose of the antibody in up to 44 adult patients with malignant solid tumors and will even
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The OmniRat technology generates fully human antibodies with specificity, affinity and manufacturability, according to WuXi. The technology eradicates time-consuming humanization of traditional mouse-derived antibodies and the need to